● Recruiting

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Condition: Non Small Cell Lung Cancer · Sponsor: Diwakar Davar

PhasePhase 2

Planned participants26

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Amy Rose, RN, BSN · 412-647-8587 · kennaj@upmc.edu

Danielle L Bednarz, RN · 412-623-1191 · bednarzdl@upmc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05669846